

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
25 November 2004 (25.11.2004)

PCT

(10) International Publication Number  
**WO 2004/101545 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 333/54**,  
333/76, A61K 31/381, A61P 35/00

(FR). **DURANTI, Eric** [FR/FR]; 258 Avenue des Filagnes,  
F-06700 SAINT LAURENT DU VAR (FR).

(21) International Application Number:  
PCT/EP2003/008811

(74) Agents: **NEVANT, Marc** et al.; CABINET BEAU DE  
LOMENTIE, 158 Rue de l'Université, F-75340 PARIS  
Cedex 07 (FR).

(22) International Filing Date: 16 May 2003 (16.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **LAB-ORATOIRE THERAMEX** [MC/MC]; 6 Avenue Prince  
Héréditaire Albert, 98000 MONACO (MC).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **LAFAY, Jean**  
[FR/FR]; 1 Rue Clément Ader, F-06100 NICE (FR).  
**RONDOT, Benoît** [FR/FR]; Parc de Montfort - Lôt  
8, Chemin du Caminon, F-06480 LA COLLE SUR  
LOUP (FR). **CARNIATO, Denis** [FR/FR]; 33 Avenue du  
Maréchal de Lattre de Tassigny, F-91460 MARCOUSSIS  
(FR). **BONNET, Paule** [FR/FR]; Villa " Rocailles ", 37E  
Route de Sospel, F-06500 MENTON (FR). **CLERC,**  
**Thierry** [FR/FR]; Le Rochefort, 114 Avenue de la  
Lanterne, F-06200 NICE (FR). **SHIELDS, Jacqueline**  
[FR/FR]; 6 Avenue George Sand, F-06100 NICE (FR).  
**DUC, Igor** [FR/FR]; 26 Rue Borniol, F-06400 CANNES

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SULFAMATE BENZOTHIOPHENE DERIVATIVES AS STEROID SULFATASE INHIBITORS



(57) Abstract: The present invention relates to sulfamate benzothiophene compounds of the formula: (I) wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, m and n are as defined in the specification. The invention also relates to pharmaceutical compositions containing these compounds and to methods of using them.

## SULFAMATE BENZOTHIOPHENE DERIVATIVES AS STEROID SULFATASE INHIBITORS

**Field of invention**

5           The present invention generally relates to steroid hormones, and more specifically relates to novel sulfamate benzothiophene derivatives which are inhibitors of the enzyme steroid sulfatase. The invention also relates to pharmaceutical compositions containing these derivatives, and to methods of using them.

**10   Background of the invention**

          The enzyme steroid sulfatase (E.C. 3.1.6.2., STS) catalyses the hydrolysis of estrone sulfate to estrone and of DHEA sulfate to DHEA (Dibbelt L, Biol. Chem, Hoppe-Seyler, 1991, 372, 173-185 and Stein C, J. Biol. Chem., 1989, 264, 13865-13872).



15           The steroid sulfatase pathway has been the focus of recent interest in the context of breast cancer, with regard to the local intra-tissue formation of estrogens from the abundant circulating pool of estrone sulfate (E<sub>1</sub>S) (Pasqualini JR, J. Steroid Biochem. Mol. Biol., 1999, 69, 287-292 and Purohit A, Mol. Cell. Endocrinol., 2001, 171, 129-135).

20           Inhibition of this enzyme would prevent E<sub>1</sub>S to yield free estrone (E<sub>1</sub>), which in turn can be transformed into estradiol (E<sub>2</sub>) by enzymatic reduction. In addition to the estrone sulfatase pathway, it is now believed that another potent estrogen, androstenediol (adiol) obtained from DHEA after hydrolysis of DHEA-S, could be another important route, in the support of growth and development of hormone  
25           dependent breast tumors.


          The formation of estrogens in humans is schematically represented in figure 1.

          In patients with hormone-dependent cancers, aromatase inhibitors are currently used to prevent estrogen synthesis. However, clinical trials showed a relative lack of efficacy for patients with estrogen receptors positive tumors  
30           (Castiglione-Gertsch M, Eur. J. Cancer, 1996, 32A, 393-395 and Jonat W, Eur. J. Cancer, 1996, 32A, 404-412). As an explanation, steroid sulfatase pathway could be another important route for estrogen formation in breast tumors.

EMATE (Ahmed S, Curr. Med. Chem., 2002, 9, 2, 263-273), estrone-3-sulfamate, is the historical standard steroid sulfatase inhibitor but with the major drawback of being estrogenic because of its mechanism of inhibition: the sulfamate moiety is cleaved during the process of enzyme inactivation, which releases E<sub>1</sub>, not  
5 from E<sub>1</sub>S but from EMATE itself (Ahmed S, J. Steroid Biochem. Mol. Biol., 2002, 80, 429-440).

**Estradiol****EMATE**

Other non steroid sulfamate compounds which release derivatives without  
10 estrogenic properties are presented as acceptable drug candidates, in particular 6,6,7-COUMATE, a standard non-estrogenic sulfatase inhibitor from the literature (Purohit A, Cancer Res., 2000, 60, 3394-3396).

**6,6,7 COUMATE**

15 Accordingly, there is a need for steroid sulfatase inhibitors with the view of treating in particular estrogen-dependent diseases.

#### **Summary of the invention**


An object of this invention is to provide sulfamate benzothiophene derivatives which are potent steroid sulfatase inhibitors.

Another object of this invention is to provide a pharmaceutical composition containing, as active ingredient, a sulfamate benzothiophene derivative as mentioned above.

Still a further object of this invention is to provide the use of a sulfamate benzothiophene derivative in the manufacture of a medicament for treating or preventing various diseases and for managing reproductive functions in women, in men as well as in female and male wild or domestic animals.

The sulfamate benzothiophene derivatives of this invention can be represented by the following general formula (I):

10



wherein:

- R<sub>1</sub> is hydrogen, a (C<sub>1</sub>-C<sub>6</sub>)alkyl, a (C<sub>2</sub>-C<sub>6</sub>)alkene, a (C<sub>3</sub>-C<sub>12</sub>)cycloalkyl or a (C<sub>3</sub>-C<sub>12</sub>)cycloalkene, wherein the cycloalkyl and cycloalkene are optionally mono- or disubstituted with a (C<sub>1</sub>-C<sub>4</sub>)alkyl;
- R<sub>2</sub> is hydrogen, a (C<sub>1</sub>-C<sub>6</sub>)alkyl or a (C<sub>3</sub>-C<sub>12</sub>)cycloalkyl;
- R<sub>3</sub> is hydrogen, a (C<sub>1</sub>-C<sub>6</sub>)alkoxy or a halogen;
- m is 0, 1, 2;
- n is 0, 1, 2;
- when m is 0, R<sub>1</sub> and R<sub>2</sub> can also form together a group -(CH<sub>2</sub>)<sub>p</sub>- in which p is 3, 4 or 5;
- the dotted line indicates that the sulfamate group (OSO<sub>2</sub>(NH<sub>2</sub>)) is in position 5- or 6- of the benzothiophene ring.

Among the compounds of formula (I), those fulfilling at least one of the following conditions, are particularly preferred:

25

- R<sub>1</sub> is hydrogen, a (C<sub>1</sub>-C<sub>6</sub>) alkyl or a (C<sub>3</sub>-C<sub>12</sub>)cycloalkyl optionally mono- or disubstituted with a (C<sub>1</sub>-C<sub>4</sub>)alkyl, preferably R<sub>1</sub> is a (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl optionally mono- or disubstituted with a (C<sub>1</sub>-C<sub>4</sub>)alkyl;
- m is 0 or 1;
- 5 - R<sub>2</sub> is hydrogen;
- R<sub>3</sub> is hydrogen;
- n is 0 or 2;
- the sulfamate group is in position 6- of the benzothiophene group.

In the description and appended claims, a (C<sub>1</sub>-C<sub>4</sub>) or (C<sub>1</sub>-C<sub>6</sub>)alkyl is  
10 understood as meaning a linear or branched saturated hydrocarbon chain having 1 to 4 or, respectively, 1 to 6 carbon atoms. Such an alkyl radical is for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl or hexyl radical.

A (C<sub>1</sub>-C<sub>6</sub>)alkoxy is understood as meaning a group -OR in which R is a (C<sub>1</sub>-C<sub>6</sub>)alkyl as defined above.

15 A (C<sub>3</sub>-C<sub>12</sub>)cycloalkyl is understood as meaning a saturated mono- or bicyclic hydrocarbon having 3 to 12 carbon atoms. A (C<sub>3</sub>-C<sub>12</sub>)cycloalkyl radical is for example a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl or adamantyl radical.

A halogen is understood as meaning a chlorine, bromine, fluorine or iodine  
20 atom.

A (C<sub>2</sub>-C<sub>6</sub>)alkene is understood as meaning a linear or branched unsaturated hydrocarbon chain having 2 to 6 carbon atoms. A (C<sub>2</sub>-C<sub>6</sub>)alkene radical is for example an ethylene or a propene, butene, pentene or hexene radical.

A (C<sub>3</sub>-C<sub>12</sub>)cycloalkene is understood as meaning an unsaturated mono- or  
25 bicyclic hydrocarbon having 3 to 12 carbon atoms. A (C<sub>3</sub>-C<sub>12</sub>)cycloalkene radical is for example a cyclopropene, cyclobutene, cyclopentene, cyclohexene, cyclooctene, cyclodecene or adamantene radical.

In view of their capability to inhibit steroid sulfatase, and thus to dry out other sources of endogenous estrogens as compared with aromatase inhibitors, the  
30 compounds of the present invention can be used alone or in combination with one or several other sexual endocrine therapeutic agents such as antiestrogens, SERMs (Selective Estrogen Receptor Modulators), antiaromatases, antiandrogens, lyase

inhibitors, progestins or LH-RH agonists or antagonists, in the treatment or prevention of estrogen-dependent disorders or diseases. The compounds of the invention can also be used for the control or management of estrogen-regulated reproductive functions such as male or female fertility, pregnancy, abortion or  
5 delivery in humans as well as in wild or domestic animal species, alone or in combination with one or several other therapeutic agents such as LH-RH agonists or antagonists, estroprogestative contraceptives, progestins, antiprogestins or prostaglandins.

The breasts being sensitive targets of estrogen-stimulated proliferation and/or  
10 differentiation, the compounds of the invention can be used in the treatment or prevention of benign breast diseases in women, gynecomastia in men and in benign or malignant breast tumors with or without metastasis both in men and women or in male or female domestic animals. The compounds of the invention can also be used in the treatment or prevention of benign or malignant diseases of the uterus or the  
15 ovary. In each case, the compounds of the invention can be used alone or in combination with one or several other sexual endocrine therapeutic agents such as those mentioned above.

As the enzyme steroid sulfatase transforms DHEA sulfate into DHEA, a precursor of active androgens (testosterone and dihydrotestosterone), the compounds  
20 of the invention can be used in the treatment or prevention of androgen-dependent diseases such as androgenic alopecia (male pattern loss) (Hoffman R et al., J. Invest. Dermatol., 2001, 117, 1342-1348) or acne (Billich A et al., 1999, WO 9952890), benign or malignant diseases of the prostate or the testis (Reed MJ, Rev. Endocr. Relat. Cancer, 1993, 45, 51-62), alone or in combination with one or several other  
25 sexual endocrine therapeutic agents, such as antiandrogens, antiestrogens, SERMs, antiaromatase, progestins, lyase inhibitors or LH-RH agonists or antagonists.

Inhibitors of steroid sulfatase are also potentially involved in the treatment of cognitive dysfunction, because they are able to enhance learning and spatial memory in the rat (Johnson DA, Brain Res, 2000, 865, 286-290). DHEA sulfate as a  
30 neurosteroid affects a number of neurotransmitter systems, including those involving acetylcholine, glutamate, and GABA, resulting in increased neuronal excitability (Wolf OT, Brain Res. Rev, 1999, 30, 264-288).

In addition, estrogens are involved in the regulation of the balance between Th<sub>1</sub> and Th<sub>2</sub> predominant immune functions and may therefore be useful in the treatment or prevention of gender-dependent auto-immune diseases such as lupus, multiple sclerosis, rheumatoid arthritis and the like (Daynes RA, J. Exp. Med, 1990, 171, 979-996). Steroid sulfatase inhibition was shown to be protective in models of contact allergy and collagen-induced arthritis in rodents (Sutters AJ, Immunology, 1997, 91, 314-321).

Studies using 2-MeOEMATE have shown that steroid sulfatase inhibitors have potent estradiol-independent growth-inhibitory effect (MacCARTHY-MOOROGH L, Cancer Research, 2000, 60, 5441-5450). A decrease in tumor volume was surprisingly observed with the compounds of the invention, with low tumor steroid sulfatase inhibition. In view of this, the compounds of the invention could lead to a decrease in cellular division because of the large interaction between such new chemical entities and the microtubular network within the cancerous cell, whatever the tissue, including breast, endometrium, uteri, prostate, testis or metastasis generated from. The compounds of the invention could therefore be useful in the treatment of non-estrogeno-dependent cancer.

Accordingly, it is another object of the invention to provide a method for treating the above-mentioned diseases or disorders, in particular estrogen-dependent diseases or disorders, i.e. estrogen-induced or estrogen-stimulated diseases or disorders (GOLOB T, Bioorg. Med. Chem., 2002, 10, 3941-3953). The method comprises administering to a subject (human or animal) in need thereof a therapeutically effective amount of a compound of formula (I).

The pharmaceutical compositions containing the active ingredient(s) may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient(s) in admixture with non-toxic pharmaceutically

acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. The tablets may also be coated by the technique described in U.S. Patents 4,256,108; 4,166,452 or 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient(s) is (are) mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules wherein the active ingredient(s) is (are) mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active ingredient(s) in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one



or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient(s) in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those mentioned above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for the preparation of an aqueous suspension by the addition of water provide the active ingredient(s) in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present. The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

The pharmaceutical compositions of the invention may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed, water, Ringer's solution and isotonic sodium chloride solution can be mentioned. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending

medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.


The compounds of the invention can be used in the treatment of the above-  
5 indicated diseases or disorders at dosage levels of the order of from about 0.0001 mg to about 10 mg/kg of body weight per day, or alternatively from about 0.01 mg to about 100 mg per patient per day.

The amount of active ingredient(s) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated  
10 and the particular mode of administration.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

15 The sulfamate benzothiophene derivatives of formula (I) can be prepared according to the following general scheme 1.

scheme 1



According to scheme 1 the 3-methoxythiophenol (1) is condensed with 2-bromo-1,1-diethoxyethane and the thio-compound intermediate (2) is cyclised with different acids: polyphosphoric acid (Bioor. Med. Chem. Lett, 1999, 9, 759-64) or methanesulfonic acid to afford the 6-methoxy-benzothiophene (3). This compound  
5 can also be prepared by reaction of a Lewis acid, trifluoroborane, with compound (2) using the conditions described by S. Graham (J. Med. Chem, 1989, 32, 2548-54).

The 6-methoxy-benzothiophene (3) is converted to the bromo derivative (4) with N-bromosuccinimid and APTS using the conditions described by Y. Fort (Tetrahedron. 1994, 50, 11893-902). (4) is transformed into an organomagnesium  
10 bromide, and then condensed with a ketone or an aldehyde to afford the monosubstituted benzothiophene (5) using standard conditions.

The disubstituted benzothiophene (9) can be prepared by alkylation of the monosubstituted compound (5) using the conditions described by Kano. S (Heterocycles, 1982, 19, 6, 1033-37).

15 The compounds where  $R_1$  and  $R_2$  form together a group  $-(CH_2)_p-$ , such as the 7-methoxy-1,2,3,4-tetrahydrodibenzothiophene ( $p = 4$ ), can be prepared using the conditions described by Oliveira. M (Tetrahedron, 2002, 58, 1709-18).

Deprotection of the methoxybenzothiophene monosubstituted (5) or disubstituted (9) with tribromoborane gave the hydroxy compounds (6) and (10)  
20 prepared using the conditions described by McOmie. J.F.W (Tetrahedron, 1968, 24, 2289-92). These compounds were transformed into the corresponding sulfamates (7) and (11) by treatment with sodium hydride, with amidochlorosulfonic acid (Nussbaumer. P, J Med Chem, 2002, 45, 4310-20), or by reaction with sulfamoyl chloride in dimethylacetamide (DMAc) (Makoto. O, Tetrahedron letters, 2000, 41,  
25 7047-51).

Oxidation of (7) and (11) by hydrogen peroxide in trifluoroacetic acid, following the conditions described by GRIVAS S. and RONNE E. (Acta Chemica Scandinavia, 1995, 49, 225-229), gave the final benzothiophenes (8) and (12).

The compounds of formula (I) where the sulfamate group is in position 5- of  
30 the benzothiophene ring can be prepared in the same way but starting from 4-methoxythiophenol.

The following examples are intended to illustrate and not to limit the scope of the invention.

**PREPARATION OF THE 3-BROMO-6-METHOXYBENZOTHIOPHENE (4)**

**EXAMPLE 1: 6-Methoxybenzothiophene (3)**

5 Bromoacetaldehyde diethyl acetal (16.50 ml, 0.11 mol) was added dropwise to a mixture of *m*-methoxybenzenethiol (1) (15 ml, 0.12 mol) and K<sub>2</sub>CO<sub>3</sub> (16.60 g, 0.12 mol) in acetone (150 ml) at room temperature. The reaction mixture was stirred for 16 h and then filtered. The solid was washed with acetone, and the combined  
10 filtrates were concentrated under vacuum. The residue was diluted with water and extracted with Et<sub>2</sub>O. The organic phase was washed with 0.5 M KOH, water, and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum to give 27.40 g of compound (2) as a dark yellow oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 1.18 (t, 6H), 3.13 (d, 2H), 3.43-3.73 (m, 4H), 3.77 (s, 3H), 4.67 (t, 1 H), 6.60-7.27 (m, 4H).

15 A solution of (2) (13.00 g, 0.051 mol) in CH<sub>2</sub>Cl<sub>2</sub> (100 ml) was added dropwise to a solution of BF<sub>3</sub>·Et<sub>2</sub>O (6.70 ml, 0.054 mol) in CH<sub>2</sub>Cl<sub>2</sub> (1000 ml) at room temperature under nitrogen atmosphere. After hydrolysis, the reaction mixture was stirred until both phases became clear. The CH<sub>2</sub>Cl<sub>2</sub> layer was separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic phases were dried  
20 over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum to give 8.68 g of a 1:10 mixture of 4 and 6-methoxybenzothiophene (3) as a dark brown oil. The crude product was used without purification.

Major isomer (3) <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 3.85 (s, 3H), 6.98 (dd, 1H), 7.23 (s, 2H), 7.35 (d, 1H), 7.68 (d, 1 H).

25 **EXAMPLE 2: 3-Bromo-6-methoxybenzothiophene (4)**

N-bromosuccinimide (14.70 g, 82.59 mmol) and p-toluenesulfonic acid (2.70 g, 15.68 mmol) were added to a solution of benzothiophene (3) (15.10 g, 92.07 mmol) in 1,2-dichloroethane (300 ml). The mixture was maintained at 70°C for 35 min, cooled in an ice bath, and the succinimide was removed by filtration. The  
30 solution was extracted with saturated sodium bicarbonate solution, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum to give 22.00 g as an oil. Crystallisation from pentane afforded a white solid (16.50 g, 74 %), mp 62°C.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 3.85 (s, 3H), 6.9 (dd, 1H), 7.50 (m, 2H), 7.65 (d, 1H)

## PREPARATION OF MONOSUBSTITUED BENZOTHIOPHENE (5)

### EXAMPLE 3: 3-Cyclohexyl-6-methoxybenzothiophene

To Mg (0.22 g, 9.05 mmol) under argon in Et<sub>2</sub>O (20 ml) was added dropwise  
5 a solution of bromide (4) (2.00 g, 8.23 mmol) in Et<sub>2</sub>O (20 ml). The mixture was  
refluxed for 2 h, a solution of cyclohexanone (1.00 ml, 9.87 mmol) in Et<sub>2</sub>O (5 ml)  
was added and the mixture was refluxed for 2 h. It was poured into iced water. The  
solution was extracted with ethyl acetate, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and  
concentrated under vacuum to give 8.00 g as an oil. Triturating from diisopropyl  
10 ether afforded 3-(1-hydroxycyclohexyl)-6-methoxybenzothiophene as a white  
powder (0.90 g, 65 %).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) : 1.20-2.00 (m, 10H), 3.80 (s, 3H), 5.30 (s, 1H), 6.93 (dd, 1H),  
7.10 (s, 1H), 7.42 (d, 1H), 7.60 (d, 1H).

To 3-(1-hydroxycyclohexyl)-6-methoxybenzothiophene (0.30 g, 1.14 mmol)  
15 under argon in dichloromethane (10 ml) was added dropwise triethylsilane (0.22 ml,  
1.37 mmol). Then, the solution was stirred at 0°C, and trifluoroacetic acid (5.00 ml,  
67.31 mmol) was added. After 2 h at room temperature the mixture was poured into  
saturated aqueous NaHCO<sub>3</sub> and ice, extracted with ethyl acetate, dried over Na<sub>2</sub>SO<sub>4</sub>,  
filtered, and concentrated under vacuum to give 0.30 g as an oil (100%).  
20 Crystallisation from diisopropyl ether afforded a white crystal (0.20 g, 70 %).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) : 1.00-2.20 (m, 11H), 2.72 (m, 1H), 3.75 (s, 3H), 6.93 (dd, 1H),  
7.01 (s, 1H), 7.43 (d, 1H), 7.58 (d, 1H).

Using the same procedure but replacing cyclohexanone by:

- cyclopentanone
- 25 - cycloheptanone
- cyclooctanone
- cyclodecanone
- 4-methylcyclohexanone
- 2-methylcyclohexanone
- 30 - 2,2-dimethylcyclopentanone
- 2-adamantanone
- propanone

- hexanone
- cyclohexanecarboxaldehyde
- cycloheptanecarboxaldehyde (prepared following J. G. Traynham et al, Tetrahedron, 7, 1959, 165-72),

5 the following compounds were respectively obtained:

**EXAMPLE 4: 3-cyclopentyl-6-methoxybenzothiophene**

<sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 1.40-2.20 (m, 8H), 2.72 (m, 1H), 3.80 (s, 3H), 6.94 (dd, 1H), 7.13 (s, 1H), 7.45 (d, 1H), 7.64 (d, 1H).

**EXAMPLE 5: 3-cycloheptyl-6-methoxybenzothiophene**

10 <sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 1.40-2.20 (m, 12H), 3.05 (m, 1H), 3.80 (s, 3H), 6.90 (dd, 1H), 7.00 (s, 1H), 7.41 (d, 1H), 7.57 (d, 1H).

**EXAMPLE 6: 3-cyclooctyl-6-methoxybenzothiophene**

<sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 1.20-2.15 (m, 14H), 3.10 (m, 1H), 3.77 (s, 3H), 6.92 (dd, 1H), 7.01 (s, 1H), 7.41 (d, 1H), 7.58 (d, 1H).

15 **EXAMPLE 7: 3-cyclodecyl-6-methoxybenzothiophene**

<sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 1.20-2.15 (m, 18H), 3.12 (m, 1H), 3.75 (s, 3H), 6.92 (dd, 1H), 7.01 (s, 1H), 7.40 (d, 1H), 7.55 (d, 1H).

**EXAMPLE 8: 3-(4-methylcyclohexyl)-6-methoxybenzothiophene**

20 <sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 0.70-2.15 (m, 12H), 2.72 (m, 0.5H, diastereoisomer), 2.99 (m, 0.5H, diastereoisomer), 3.76 (s, 3H), 6.92 (dd, 1H), 7.02 (s, 1H), 7.41 (d, 1H), 7.58 (d, 1H).

**EXAMPLE 9: 3-(2-methylcyclohexyl)-6-methoxybenzothiophene**

25 <sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 0.70-2.20 (m, 12H), 2.70 (m, 0.5H, diastereoisomer), 3.02 (m, 0.5H, diastereoisomer), 3.75 (s, 3H), 6.92 (dd, 1H), 7.02 (s, 1H), 7.40 (d, 1H), 7.55 (d, 1H).

**EXAMPLE 10: 3-(2,2-dimethylcyclopentyl)-6-methoxybenzothiophene**

<sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 0.70 (s, 3H), 1.10 (s, 3H), 1.45-2.20 (m, 6H), 2.93 (m, 1H), 3.78 (s, 3H), 7.02 (dd, 1H), 7.04 (s, 1H), 7.43 (d, 1H), 7.60 (d, 1H).

**EXAMPLE 11: 3-(2-adamantyl)-6-methoxybenzothiophene**

30 <sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 1.40-2.40 (m, 14H), 3.19 (br s, 1H), 3.79 (s, 3H), 6.92 (dd, 1H), 7.08 (s, 1H), 7.43 (d, 1H), 7.60 (d, 1H).

**EXAMPLE 12: 3-propyl-6-methoxybenzothiophene**

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.95 (t, 3H), 1.68 (m, 2H), 2.78 (t, 2H), 3.79 (s, 3H), 6.92 (dd, 1H), 7.00 (s, 1H), 7.43 (d, 1H), 7.58 (d, 1H).

**EXAMPLE 13: 3-hexyl-6-methoxybenzothiophene**

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.85 (t, 3H), 1.10-1.80 (m, 8H), 2.82 (t, 2H), 3.79 (s, 3H), 6.92 (dd, 1H), 7.01 (s, 1H), 7.45 (d, 1H), 7.58 (d, 1H).

**EXAMPLE 14: 3-cyclohexylmethyl-6-methoxybenzothiophene**

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.75-1.85 (m, 11H), 2.70 (d, 2H), 3.80 (s, 3H), 6.92 (dd, 1H), 7.00 (s, 1H), 7.42 (d, 1H), 7.59 (d, 1H).

**EXAMPLE 15: 3-cycloheptylmethyl-6-methoxybenzothiophene**

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.00-1.90 (m, 13H), 2.71 (d, 2H), 3.80 (s, 3H), 6.93 (dd, 1H), 7.00 (s, 1H), 7.42 (d, 1H), 7.59 (d, 1H).

**PREPARATION OF MONOSUBSTITUTED BENZOTHIOPHENOL (6)**

**EXAMPLE 16: 3-Cyclohexyl-benzothiophene-6-ol**

A solution of 3-cyclohexyl-6-methoxybenzothiophene (4.00 g, 16.0 mmol) in 40 ml of dichloromethane is added at room temperature to a solution of boron tribromide (24 ml, 24 mmol). After 2h at room temperature the mixture was hydrolysed with saturated aqueous NaHCO<sub>3</sub>, extracted with dichloromethane, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuum to give the alcohol (3.60 g as an oil, 97%).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.10-2.10 (m, 10H), 2.80 (m, 1H), 6.78 (dd, 1H), 6.94 (s, 1H), 7.17 (d, 1H), 7.48 (d, 1H), 9.42 (s, 1H, OH).

Using the same procedure but replacing 3-cyclohexyl-6-methoxybenzothiophene by:

- 3-cyclopentyl-6-methoxybenzothiophene
- 3-cycloheptyl-6-methoxybenzothiophene
- 3-cyclooctyl-6-methoxybenzothiophene
- 3-cyclodecyl-6-methoxybenzothiophene
- 3-(4-methylcyclohexyl)-6-methoxybenzothiophene
- 3-(2-methylcyclohexyl)-6-methoxybenzothiophene
- 3-(2,2-dimethylcyclopentyl)-6-methoxybenzothiophene
- 3-(2-adamantyl)-6-methoxybenzothiophene
- 3-propyl-6-methoxybenzothiophene



- 3-hexyl-6-methoxybenzothiophene
- 3-cyclohexylmethyl-6-methoxybenzothiophene
- 3-cycloheptylmethyl-6-methoxybenzothiophene,

the following compounds were respectively obtained:

5 **EXAMPLE 17: 3-cyclopentyl-benzothiophene-6-ol**

mp 116°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) : 1.45-2.20 (m, 8H), 3.25 (m, 1H), 6.78 (dd, 1H), 6.96 (s, 1H), 7.15 (d, 1H), 7.47 (d, 1H), 9.45 (s, 1H, OH).

**EXAMPLE 18: 3-cycloheptyl-benzothiophene-6-ol**

10 mp 140°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) : 1.35-2.15 (m, 12H), 3.00 (m, 1H), 6.79 (dd, 1H), 6.94 (s, 1H), 7.17 (d, 1H), 7.48 (d, 1H), 9.45 (s, 1H, OH).

**EXAMPLE 19: 3-cyclooctyl-benzothiophene-6-ol**

mp 100°C

15 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) : 1.35-2.10 (m, 14H), 3.07 (m, 1H), 6.78 (dd, 1H), 6.95 (s, 1H), 7.15 (d, 1H), 7.47 (d, 1H), 9.42 (s, 1H, OH).

**EXAMPLE 20: 3-cyclodecyl-benzothiophene-6-ol**

mp 108°C

20 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) : 1.30-2.10 (m, 18H), 3.22 (m, 1H), 6.79 (dd, 1H), 6.99 (s, 1H), 7.15 (d, 1H), 7.48 (d, 1H), 9.42 (s, 1H, OH).

**EXAMPLE 21: 3-(4-methylcyclohexyl)-benzothiophene-6-ol**

mp 132°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.70-2.10 (m, 12H), 2.70 (m, 1H), 6.80 (dd, 1H), 6.92 (s, 1H), 7.15 (d, 1H), 7.48 (d, 1H), 9.42 (s, 1H, OH).

25 **EXAMPLE 22: 3-(2-methylcyclohexyl)-benzothiophene-6-ol**

mp 125°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.60-2.20 (m, 12H), 3.05 (m, 1H), 6.80 (dd, 1H), 6.90 (s, 1H), 7.16 (d, 1H), 7.50 (d, 1H), 9.45 (s, 1H, OH).

**EXAMPLE 23: 3-(2,2-dimethylcyclopentyl)-benzothiophene-6-ol**

30 mp 90°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.70 (s, 3H), 1.09 (s, 3H), 1.45-2.20 (m, 6H), 2.92 (dd, 1H), 6.80 (dd, 1H), 6.99 (s, 1H), 7.17 (d, 1H), 7.51 (d, 1H), 9.45 (s, 1H, OH).

**EXAMPLE 24: 3-(2-adamantyl)-benzothiophene-6-ol**

mp 184°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.40-2.40 (m, 14H), 3.16 (br s, 1H), 6.80 (dd, 1H), 7.00 (s, 1H), 7.17 (d, 1H), 7.50 (d, 1H), 9.43 (s, 1H, OH).5 **EXAMPLE 25: 3-propyl-benzothiophene-6-ol**

mp 56°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.97 (t, 3H), 1.68 (m, 2H), 2.79 (t, 2H), 6.80 (dd, 1H), 6.96 (s, 1H), 7.17 (d, 1H), 7.50 (d, 1H), 9.46 (s, 1H, OH).**EXAMPLE 26: 3-hexyl-benzothiophene-6-ol**

10 mp 68°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.85 (t, 3H), 1.10-1.80 (m, 8H), 2.78 (t, 2H), 6.79 (dd, 1H), 6.95 (s, 1H), 7.16 (d, 1H), 7.48 (d, 1H), 9.45 (s, 1H, OH).**EXAMPLE 27: 3-cyclohexylmethyl-benzothiophene-6-ol**

mp 97°C

15 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.75-1.80 (m, 11H), 2.68 (d, 2H), 6.78 (dd, 1H), 6.91 (s, 1H), 7.16 (d, 1H), 7.49 (d, 1H), 9.45 (s, 1H, OH).**EXAMPLE 28: 3-cycloheptylmethyl-benzothiophene-6-ol**

mp 82°C

20 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.00-1.90 (m, 13H), 2.72 (d, 2H), 6.80 (dd, 1H), 6.92 (s, 1H), 7.18 (d, 1H), 7.49 (s, 1H), 9.48 (s, 1H, OH).**PREPARATION OF SULFAMIC ACID MONOSUBSTITUTED BENZOTHIOPHENYL ESTER (7)****EXAMPLE 29: Sulfamic acid, 3-cyclohexyl-benzothiophene-6-yl ester**

25 Sodium hydride (0.60 g, 24.8 mmol) was carefully added to a solution of 3-cyclohexyl-benzothiophene-6-ol (3.60 g, 15.50 mmol) in dry DMF (36 ml) at 0°C. After being stirred for 30 min at room temperature and 30 min at 50°C, the mixture was cooled (ice/water) and amidochlorosulfonic acid (4.45 g, 38.00 mmol) was added. After 3 h at room temperature the mixture was hydrolysed with saturated aqueous NH<sub>4</sub>Cl, extracted with ethyl acetate, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and

30 concentrated under vacuum to give the crude product (4.80 g as oil). Flash chromatography on silica gel (toluene/1,4-dioxan: 8/2) yielded a limpid oil which was crystallised from ethanol to give the title product (0.50 g, 10%, mp 128°C).

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ ) : 1.15-2.20 (m, 10H), 2.90 (m, 1H), 7.18 (s, 1H), 7.24 (dd, 1H), 7.30 (d, 1H), 7.32 (s, 1H), 7.98 (s, 2H,  $\text{NH}_2$ ).

Using the same procedure but replacing 3-cyclohexylbenzothiophene-6-ol by:

- 3-cyclopentyl-benzothiophene-6-ol
- 5    - 3-cycloheptyl-benzothiophene-6-ol
- 3-cyclooctyl-benzothiophene-6-ol
- 3-cyclodecyl-benzothiophene-6-ol
- 3-(4-methylcyclohexyl)-benzothiophene-6-ol
- 3-(2-methylcyclohexyl)-benzothiophene-6-ol
- 10    - 3-(2,2-dimethylcyclopentyl)-benzothiophene-6-ol
- 3-(2-adamantyl)-benzothiophene-6-ol
- 3-propyl-benzothiophene-6-ol
- 3-hexyl-benzothiophene-6-ol
- 3-cyclohexylmethyl-benzothiophene-6-ol
- 15    - 3-cycloheptylmethyl-benzothiophene-6-ol,

the following compounds were respectively obtained:

**EXAMPLE 30: Sulfamic acid, 3-cyclopentyl-benzothiophene-6-yl ester**

mp 110°C

20     $^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ ) : 1.50-2.30 (m, 8H), 3.39 (m, 1H), 7.20 (s, 1H), 7.72 (dd, 1H), 7.78 (d, 1H), 7.95 (s, 2H,  $\text{NH}_2$ ).

**EXAMPLE 31: Sulfamic acid, 3-cycloheptyl-benzothiophene-6-yl ester**

mp 132°C

$^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ ): 1.35-2.20 (m, 12H), 3.12 (m, 1H), 7.19 (s, 1H), 7.24 (dd, 1H), 7.75 (d, 1H), 7.80 (d, 1H), 7.95 (s, 2H,  $\text{NH}_2$ ).

25    **EXAMPLE 32: Sulfamic acid, 3-cyclooctyl-benzothiophene-6-yl ester**

mp 126°C

$^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ ) : 0.90-2.20 (m, 14H), 3.18 (m, 1H), 7.17 (s, 1H), 7.23 (dd, 1H), 7.76 (d, 1H), 7.80 (d, 1H), 7.95 (s, 2H,  $\text{NH}_2$ ).

**EXAMPLE 33: Sulfamic acid, 3-cyclodecyl-benzothiophene-6-yl ester**

30    mp 98°C

$^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ ): 1.30-2.10 (m, 18H), 3.31 (m, 1H), 7.20 (s, 1H), 7.23 (dd, 1H), 7.76 (d, 1H), 7.79 (d, 1H), 7.96 (s, 2H,  $\text{NH}_2$ ).

**EXAMPLE 34: Sulfamic acid, 3-(4-methylcyclohexyl)-benzothiophene-6-yl ester**

mp 132°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.75-2.15 (m, 12H), 2.55 (m, 1H), 7.25 (s, 1H), 7.55 (dd, 1H), 7.60 (d, 1H), 7.70 (d, 1H), 8.25 (s, 2H, NH<sub>2</sub>).**5 EXAMPLE 35: Sulfamic acid, 3-(2-methylcyclohexyl)-benzothiophene-6-yl ester**

mp 110°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.65-2.30 (m, 12H), 3.15 (m, 1H), 7.05-7.35 (m, 2H), 7.70-7.89 (m, 2H), 7.97 (s, 2H, NH<sub>2</sub>).**EXAMPLE 36: Sulfamic acid, 3-(2,2-dimethylcyclopentyl)-benzothiophene-6-yl****10 ester**

mp 72°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.70 (s, 3H), 1.10 (s, 3H), 1.45-2.30 (m, 6H), 3.02 (dd, 1H), 7.20 (s, 1H), 7.23 (dd, 1H), 7.78 (d, 1H), 7.80 (s, 1H), 7.96 (s, 2H, NH<sub>2</sub>).**EXAMPLE 37: Sulfamic acid, 3-(2-adamantyl)-benzothiophene-6-yl ester****15 mp 185°C**<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.50-2.40 (m, 12H), 3.37 (br s, 1H), 7.24 (m, 2H), 7.80 (d, 1H), 7.82 (s, 1H), 7.97 (s, 2H, NH<sub>2</sub>).**EXAMPLE 38: Sulfamic acid, 3-propyl-benzothiophene-6-yl ester**

mp 112°C

**20** <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.96 (t, 3H), 1.70 (m, 2H), 2.88 (t, 2H), 7.19 (s, 1H), 7.24 (dd, 1H), 7.78 (d, 1H), 7.80 (s, 1H), 7.97 (s, 2H, NH<sub>2</sub>).**EXAMPLE 39: Sulfamic acid, 3-hexyl-benzothiophene-6-yl ester**

Mp 125°C

**25** <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.95 (t, 3H), 1.10-1.80 (m, 8H), 2.88 (t, 2H), 7.19 (s, 1H), 7.22 (dd, 1H), 7.77 (d, 1H), 7.79 (s, 1H), 7.96 (s, 2H, NH<sub>2</sub>).**EXAMPLE 40: Sulfamic acid, 3-cyclohexylmethyl-benzothiophene-6-yl ester**

Mp 115°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.80-1.80 (m, 11H), 2.78 (d, 2H), 7.16 (s, 1H), 7.24 (dd, 1H), 7.77 (d, 1H), 7.79 (s, 1H), 7.97 (s, 2H, NH<sub>2</sub>).**30 EXAMPLE 41: Sulfamic acid, 3-cycloheptylmethyl-benzothiophene-6-yl ester**

mp 90°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.00-2.00 (m, 13H), 2.82 (d, 2H), 7.18 (s, 1H), 7.22 (dd, 1H), 7.78 (d, 1H), 7.80 (s, 1H), 7.97 (s, 2H, NH<sub>2</sub>).

**PREPARATION OF MONO OR DI-OXIDIZED MONOSUBSTITUTED COMPOUNDS (8)**

5 **EXAMPLE 42: Sulfamic acid, 3-cyclohexyl-benzothiophene-6-yl-1-oxide ester**

To a solution of sulfamic acid, 3-cyclohexyl-benzothiophene-6-yl ester (1.00 g, 3.21 mmol) in dichloromethane (20 ml) and trifluoroacetic acid (5 ml) was added 35% aqueous hydrogen peroxide (0.35 ml, 3.42 mmol, 1.05 equivalent). After 2 h at 50°C the mixture was hydrolysed with saturated aqueous NaHCO<sub>3</sub>, extracted with  
10 dichloromethane, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum to give the crude product. Flash chromatography on silica gel (toluene / 1,4-dioxan : 6/4) yielded a limpid oil which was crystallised from ethanol to give the title product (0.25 g, 24%, mp 110°C).

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) : 1.10-2.15 (m, 10H), 2.72 (m, 1H), 7.10 (s, 1H), 7.45 (dd, 1H),  
15 7.64 (d, 1H), 7.84 (d, 1H), 8.16 (s, 2H, NH<sub>2</sub>).

Using the same procedure but replacing the sulfamic acid, 3-cyclohexyl-benzothiophene-6-yl ester by:

- Sulfamic acid, 3-cyclodecyl-benzothiophene-6-yl ester,

the following compound was obtained:

20 **EXAMPLE 43: Sulfamic acid, 3-cyclodecyl-benzothiophene-6-yl-1-oxide ester**  
mp 146°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) : 1.35-2.10 (m, 18H), 3.12 (m, 1H), 7.15 (s, 1H), 7.45 (dd, 1H), 7.62 (d, 1H), 7.83 (d, 1H), 8.15 (s, 2H, NH<sub>2</sub>).

Using the procedure of example 42 but with 2.2 equivalents of hydrogen  
25 peroxide, the following compound was obtained:

**EXAMPLE 44: Sulfamic acid, 3-cyclohexyl-benzothiophene-6-yl-1,1-dioxide ester**

mp 180°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.15-2.15 (m, 10H), 2.52 (m, 1H), 7.30 (s, 1H), 7.53 (dd, 1H),  
30 7.63 (d, 1H), 7.71 (d, 1H), 8.25 (s, 2H, NH<sub>2</sub>).

Using the same procedure but replacing the sulfamic acid, 3-cyclohexyl-benzothiophene-6-yl ester by:

- Sulfamic acid, 3-cycloheptyl-benzothiophene-6-yl ester
- Sulfamic acid, 3-cyclooctyl-benzothiophene-6-yl ester
- Sulfamic acid, 3-cyclodecyl-benzothiophene-6-yl ester
- Sulfamic acid, 3-(4-methylcyclohexyl)-benzothiophene-6-yl ester
- 5 - Sulfamic acid, 3-(2-methylcyclohexyl)-benzothiophene-6-yl ester
- Sulfamic acid, 3-(2,2-dimethylcyclopentyl)-benzothiophene-6-yl ester
- Sulfamic acid, 3-(2-adamantyl)-benzothiophene-6-yl ester
- Sulfamic acid, 3-propyl-benzothiophene-6-yl ester
- Sulfamic acid, 3-hexyl-benzothiophene-6-yl ester
- 10 - Sulfamic acid, 3-cyclohexylmethyl-benzothiophene-6-yl ester
- Sulfamic acid, 3-cycloheptylmethyl-benzothiophene-6-yl ester,

the following compounds were respectively obtained:

**EXAMPLE 45: Sulfamic acid, 3-cycloheptyl-benzothiophene-6-yl-1,1-dioxide ester**

15 mp 137°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.35-2.15 (m, 12H), 2.75 (m, 1H), 7.32 (s, 1H), 7.52 (dd, 1H), 7.61 (d, 1H), 7.70 (d, 1H), 8.25 (s, 2H, NH<sub>2</sub>).

**EXAMPLE 46: Sulfamic acid, 3-cyclooctyl-benzothiophene-6-yl-1,1-dioxide ester**

20 mp 122°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.35-2.10 (m, 14H), 2.81 (m, 1H), 7.32 (s, 1H), 7.52 (dd, 1H), 7.61 (d, 1H), 7.70 (d, 1H), 8.22 (s, 2 H, NH<sub>2</sub>).

**EXAMPLE 47: Sulfamic acid, 3-cyclodecyl-benzothiophene-6-yl-1,1-dioxide ester**

25 mp 102°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.35-2.10 (m, 18H), 2.97 (m, 1H), 7.38 (s, 1H), 7.52 (dd, 1H), 7.60 (d, 1H), 7.70 (d, 1H), 8.22 (s, 2 H, NH<sub>2</sub>).

**EXAMPLE 48: Sulfamic acid, 3-(4-methylcyclohexyl)-benzothiophene-6-yl -1,1-dioxide ester**

30 mp 170°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.75-2.20 (m, 12H), 2.83 (m, 1H), 7.18 (s, 1H), 7.22 (dd, 1H), 7.78 (d, 1H), 7.80 (d, 1H), 7.95 (s, 2 H, NH<sub>2</sub>).

**EXAMPLE 49: Sulfamic acid, 3-(2-methylcyclohexyl)-benzothiophene-6-yl -1,1-dioxide ester**

mp 92°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.70-2.45 (m, 12H), 2.85 (m, 1H), 7.25 (s, 1H), 7.52 (m, 3H),  
5 8.25 (s, 2 H, NH<sub>2</sub>).

**EXAMPLE 50: Sulfamic acid, 3-(2,2-dimethylcyclopentyl)-benzothiophene-6-yl -1,1-dioxide ester**

mp 172°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.90 (s, 3H), 1.16 (s, 3H), 1.50-2.15 (m, 6H), 2.66 (t, 1H), 7.49  
10 (s, 1H), 7.52 (dd, 1H), 7.61 (d, 1H), 7.70 (d, 1H), 8.24 (s, 2 H, NH<sub>2</sub>).

**EXAMPLE 51: Sulfamic acid, 3-(2-adamantyl)-benzothiophene-6-yl-1,1-dioxide ester**

mp 230°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.45-2.45 (m, 14H), 3.04 (br s, 1H), 7.38 (s, 1H), 7.53 (d, 1H),  
15 7.64 (d, 1H), 7.70 (d, 1H), 8.25 (s, 2 H, NH<sub>2</sub>).

**EXAMPLE 52: Sulfamic acid, 3-propyl-benzothiophene-6-yl-1,1-dioxide ester**

mp 159°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.99 (t, 3H), 1.70 (m, 2H), 2.49 (t, 2H), 7.29 (s, 1H), 7.52 (dd,  
1H), 7.63 (d, 1H), 7.73 (d, 1H), 8.50 (s, 2H, NH<sub>2</sub>).

20 **EXAMPLE 53: Sulfamic acid, 3-hexyl-benzothiophene-6-yl-1,1-dioxide ester**

mp 98°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.85 (t, 3H), 1.10-1.80 (m, 8H), 2.50 (t, 2H), 7.30 (s, 1H), 7.52  
(dd, 1H), 7.62 (d, 1H), 7.73 (d, 1H), 8.27 (s, 2H, NH<sub>2</sub>).

**EXAMPLE 54: Sulfamic acid, 3-cyclohexylmethyl-benzothiophene-6-yl-1,1-dioxide ester**

25

mp 132°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.80-1.95 (m, 11H), 2.40 (d, 2H), 7.30 (s, 1H), 7.53 (dd, 1H),  
7.62 (d, 1H), 7.72 (d, 1H), 8.25 (s, 2H, NH<sub>2</sub>).

**EXAMPLE 55: Sulfamic acid, 3-cycloheptylmethyl-benzothiophene-6-yl-1,1-**

30 **dioxide ester**

mp 135°C

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.00-2.15 (m, 13H), 2.45 (d, 2H), 7.29 (s, 1H), 7.53 (dd, 1H), 7.62 (d, 1H), 7.73 (d, 1H), 8.25 (s, 2H, NH<sub>2</sub>).

**PREPARATION OF DISUBSTITUTED 6-METHOXY-BENZOTHIOPHENE (9)**

5 **EXAMPLE 56: 3-cycloheptyl-6-methoxy-2-methyl-benzothiophene**

To a solution of 3-cycloheptyl-6-methoxy-benzothiophene (2.00 g, 7.69 mmol) in dry THF (20 ml) at -70°C was added dropwise a 2.5 M solution of n-butyl lithium in hexane (5 ml, 12.16 mmol). Then, the mixture was warmed to -30°C during 10 min and chilled at -70°C for the addition of iodomethane (1.0 ml, 15.38 mmol). The mixture was warmed to room temperature overnight. It was hydrolysed with saturated aqueous NH<sub>4</sub>Cl, extracted with ethyl acetate, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and concentrated under vacuum to give 2.1 g of an oil. Flash chromatography on silica gel (heptane / ethyl acetate : 1/1) yielded a limpid oil (1.50 g, 72 %) which was used without further purification.

15 <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 1.35-2.15 (m, 12H), 2.29 (s, 3H), 3.00 (m, 1H), 3.80 (s, 3H), 7.00 (s, 1 H), 7.04 (d, 1H), 7.49 (d, 1H).

Using the same procedure but replacing iodomethane by:

- bromobutane,

the following compound was obtained:

20 **EXAMPLE 57: 3-cycloheptyl-6-methoxy-2-butyl-benzothiophene**

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>): 0.90 (t, 3H), 1.10-2.20 (m, 16H), 2.75 (t, 2H), 3.04 (m, 1H), 3.80 (s, 3H), 7.00 (s, 1 H), 7.05 (d, 1H), 7.51 (d, 1H).

**EXAMPLE 58: 7-methoxy-1,2,3,4-tetrahydro-dibenzothiophene**

This compound was prepared using the conditions described by Oliveira. M  
25 (*Tetrahedron*, 2002, 58, 1709-18).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.92 (m, 4H), 2.72 (m, 2H), 2.83 (m, 2H), 3.89 (s, 3H), 6.97 (dd, 1 H), 7.30 (d, 1H), 7.47 (d, 1H).

**PREPARATION OF DISUBSTITUTED BENZOTHIOPHENE-OL (10)**

Following the procedure used for the monosubstituted compounds, but  
30 replacing 3-cyclohexyl-6-methoxy-benzothiophene by:

- 3-cycloheptyl-2-methyl-6-methoxy-benzothiophene
- 3-cycloheptyl-6-methoxy-2-butyl-benzothiophene



- 7-methoxy-1,2,3,4-tetrahydro-dibenzothiophene,

the following compounds were respectively obtained:

**EXAMPLE 59: 3-cycloheptyl-2-methyl-benzothiophene-6-ol**

mp 96°C

5 <sup>1</sup>H-NMR (DMSOd<sub>6</sub>): 1.30-2.15 (m, 12H), 2.44 (s, 3H), 3.01 (m, 1H), 6.87 (d, 1H), 6.97 (s, 1H), 7.34 (d, 1H), 9.31 (s, 1H, OH).

**EXAMPLE 60: 3-cycloheptyl-2-butyl-benzothiophene-6-ol**

limpid oil

<sup>1</sup>H-NMR (DMSOd<sub>6</sub>): 0.92 (t, 3H), 1.15-2.20 (m, 16H), 2.80 (t, 2H), 3.02 (m, 1H),  
10 6.85 (d, 1H), 6.95 (s, 1H), 7.32 (d, 1H), 9.22 (s, 1H, OH).

**EXAMPLE 61: 1,2,3,4-tetrahydro-dibenzothiophene-7-ol**

mp 116°C

<sup>1</sup>H-NMR (CDCl<sub>3</sub>): 1.90 (m, 4H), 2.68 (m, 2H), 2.79 (m, 2H), 4.98 (br s, 1H, OH),  
6.88 (dd, 1 H), 7.20 (d, 1H), 7.42 (d, 1H).

15 **PREPARATION OF SULFAMIC ACID DISUBSTITUTED BENZOTHIOPHENYL ESTER (11)**

Following the procedure used for the monosubstituted compounds but replacing 3-cyclohexyl-benzothiophene-6-ol by:

- 3-cycloheptyl-2-methyl-benzothiophene-6-ol
- 20 - 3-cycloheptyl-2-butyl-benzothiophene-6-ol
- 1,2,3,4-tetrahydro-dibenzothiophene-7-ol,

the following compounds were respectively obtained:

**EXAMPLE 62: Sulfamic acid, 3-cycloheptyl-2-methyl-benzothiophene-6-yl ester**

mp 107°C

25 <sup>1</sup>H-NMR (DMSOd<sub>6</sub>): 1.40-2.20 (m, 12H), 2.46 (s, 3H), 3.14 (m, 1H), 7.20 (s, 1H), 7.30 (dd, 1H), 7.60 (d, 1H), 8.00 (s, 2H, NH<sub>2</sub>).

**EXAMPLE 63: Sulfamic acid, 3-cycloheptyl-2-butyl-benzothiophene-6-yl ester**

limpid oil

<sup>1</sup>H-NMR (DMSOd<sub>6</sub>): 0.91 (t, 3H), 1.15-2.20 (m, 16H), 2.77 (t, 2H), 3.11 (m, 1H),  
30 7.15 (s, 1H), 7.32 (d, 1H), 7.59 (d, 1H), 8.04 (s, 2H, NH<sub>2</sub>).

**EXAMPLE 64: Sulfamic acid, 1,2,3,4-tetrahydro-dibenzothiophene-7-yl ester**

mp 165°C

<sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 1.87 (m, 4H), 2.70 (m, 2H), 2.82 (m, 2H), 7.28 (dd, 1 H), 7.66 (d, 1H), 7.72 (d, 1H).

#### PREPARATION OF DIOXIDIZED DISUBSTITUTED COMPOUNDS (12)

Following the procedure used for the monosubstituted compounds but  
5 replacing the sulfamic acid, 3-cycloheptyl-benzothiophene-6-ol ester by:

- Sulfamic acid, 3-cycloheptyl-2-methyl-benzothiophene-6-ol ester
- Sulfamic acid, 3-cycloheptyl-2-butyl-benzothiophene-6-ol ester
- Sulfamic acid, 1,2,3,4-tetrahydro-dibenzothiophene-7-ol ester,

the following compounds were respectively obtained:

10 **EXAMPLE 65: Sulfamic acid, 3-cycloheptyl-2-methyl-benzothiophene-6-yl-1,1-dioxide ester**

mp 90°C

<sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 1.30-2.20 (m, 12H), 2.48 (s, 3H), 2.76 (m, 1H), 7.28 (s, 1H), 7.41 (d, 1H), 7.52 (d, 1H), 8.27 (s, 2H, NH<sub>2</sub>).

15 **EXAMPLE 66: Sulfamic acid, 3-cycloheptyl-2-butyl-benzothiophene-6-yl-1,1-dioxide ester**

limpid oil

<sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 0.91 (t, 3H), 1.15-2.15 (m, 16H), 2.75 (m, 1H), 2.90 (t, 2H), 7.25 (s, 1H), 7.40 (d, 1H), 7.56 (d, 1H), 8.31 (s, 2H, NH<sub>2</sub>).

20 **EXAMPLE 67: Sulfamic acid, 1,2,3,4-tetrahydro-dibenzothiophene-7-yl-1,1-dioxide ester**

mp 229°C

<sup>1</sup>H-NMR (DMSO<sub>d</sub><sub>6</sub>): 1.78 (m, 4H), 2.30-2.70 (m, 4H), 7.54 (dd, 1 H), 7.61 (d, 1H), 7.74 (d, 1H).

#### 25 **BIOLOGICAL TEST RESULTS**

##### **INHIBITION OF STEROID SULFATASE *IN VITRO***

Estrone sulfate (E<sub>1</sub>S) is a major circulating plasma estrogen that is converted by the steroid sulfatase enzyme into estrone (E<sub>1</sub>), which in turn can be transformed into estradiol (E<sub>2</sub>) by enzymatic reduction. Steroid sulfatase activity is present in  
30 most tissues (uterus, liver, breast, etc..) and is significantly higher in malignant than in normal breast tissue. The close association of estrogens with the promotion of the

growth and development of breast cancer has long been recognized, therefore steroid sulfatase appears as a potential target to inhibit *in situ* formation of estrogens.

Potent inhibitors of this enzyme, containing a sulfamate moiety which is believed to be involved in the irreversible inhibition of steroid sulfatase, have been synthesized. To date the most active compound is EMATE, estrone-3-sulfamate, but its estrogenic activity has rendered this compound unsuitable for use in the treatment of hormone-dependent-tumors. Numerous structurally diversified inhibitors of steroid sulfatase have been reported among which, 6,6,7-COUMATE emerged as a standard non-steroidal inhibitor lacking estrogenic properties.

#### 10 **In vitro results**

Two *in vitro* models on whole cells were used. The JEG-3 cell line, derived from a human placental choriocarcinoma, is spontaneously very rich in human estrone sulfatase and therefore, a useful practical biological system to screen in a 96-well microplate format a large number of compounds and evaluate putative steroid sulfatase inhibitors *in vitro*. Despite a lower content in steroid sulfatase activity, the MCF-7 cells constitute another suitable model to test steroid sulfatase inhibitors on human breast adenocarcinoma cells. Moreover, these cells were used in the *in vivo* model of hormone-dependent induced xenografts.

#### **Estrone sulfatase assay on cells**

20 Whole-cell assays were performed as originally described by Duncan *et al.* (Cancer Res., 1993, 53: 298-303) on intact MCF-7 cell monolayers. Assays were carried out with cells in logarithmic growth phase, on 96-well (JEG-3) or 24-well (MCF-7) microplates. Twenty-four hours (JEG-3) or 72 h (MCF-7) before studies, cells were seeded in de complemented fetal calf serum (dFCS) supplemented medium. Then, the seeding medium was removed and the cells were rinsed with PBS to eliminate any trace of dFCS. Then,  $^3\text{H-E}_1\text{S}$  was added, followed by test compounds ranging from  $10^{-12}$  M to  $10^{-5}$  M. After 4 h (JEG-3) or 20 h (MCF-7) of treatment, the medium was transferred into either 96-deep-well microplates (JEG-3) or plastic tubes (MCF-7) and centrifuged at  $200 \times g$  for 10 min to pellet cells before  
30 toluene extraction. A fraction of medium was used for toluene extraction in order to separate conjugated substrate and non-conjugated products. The radioactivity in the toluene phase was measured by liquid scintillation counting (LSC). Finally, estrone

- sulfatase activity was expressed in pmoles of  $^3\text{H-E}_1 + ^3\text{H-E}_2$  formed per 4 or 20 hours and per  $\mu\text{g}$  DNA and estrone sulfatase inhibition in percentage of control activity without inhibitor. A non linear fit analysis (GraphPad Prism Software) of % inhibition vs. inhibitor concentrations allowed for the determination of 50 % inhibitory concentration ( $\text{IC}_{50}$ ): the lowest  $\text{IC}_{50}$  corresponds to the most potent inhibitors (Table 1).

**Table 1: Inhibition of estrone sulfatase on whole-cell assays**

Compounds	JEG-3 cells		MCF-7 cells	
	$\text{IC}_{50}$ (nM) $\pm$ S.E.M.	n	$\text{IC}_{50}$ (nM) $\pm$ S.E.M.	n
EMATE	$3.2 \pm 0.2$	4	$0.06 \pm 0.01$	18
6,6,7-COUMATE	$4.5 \pm 0.6$	37	$0.33 \pm 0.06$	24
Ex 30	$78.8 \pm 39.8$	5		
Ex 31	$101.8 \pm 58.0$	5		
Ex 32	$433.7 \pm 94.8$	5		
Ex 33	$743.8 \pm 139.6$	5		
Ex 34	$317.7 \pm 42.9$	5		
Ex 35	$146.8 \pm 16.3$	4		
Ex 36	$128.5 \pm 14.2$	4		
Ex 37	$92.4 \pm 15.6$	5		
Ex 42	$7.0 \pm 1.2$	5	$0.16 \pm 0.03$	4
Ex 44	$10.9 \pm 2.6$	5	$0.24 \pm 0.05$	4
Ex 47	$52.1 \pm 4.4$	5	$0.08 \pm 0.01$	4
Ex 48	$7.6 \pm 1.3$	5	$0.09 \pm 0.02$	4
Ex 49	$2.6 \pm 0.4$	4		
Ex 50	$2.5 \pm 0.5$	4		

Ex 52	24.7 ± 5.0	5		
Ex 53	12.5 ± 3.3	5		
Ex 54	10.0 ± 1.2	4	0.10 ± 0.03	4
Ex 55	7.7 ± 0.4	4	0.05 ± 0.01	6
Ex 64	565.8 ± 129.6	5		
Ex 65	31.7 ± 9.9	4		

Among the tested compounds, Ex 42, Ex 44, Ex 48, Ex 49, Ex 50, Ex 54 and Ex 55 showed a strong inhibition (IC<sub>50</sub> of about 10 nM) of human estrone sulfatase activity in JEG-3 cells. These compounds were checked for residual estrogenic activity *in vivo* in the classical uterotrophic assay after 3-day administration by oral route in prepubescent female rats.

#### INHIBITION OF STEROID SULFATASE *IN VIVO*

##### Residual estrogenic activity *in vivo*

Prepubescent female rats were orally treated at 1 mg/rat/day for 3 days. On the day following the last treatment, uteri were removed and wet weight were recorded.

The results are expressed as % of stimulation of uterus weight in comparison with controls.

**Table 2: residual estrogenic activity**

Compound	% stimulation	Number of animals
6,6,7 COUMATE	3%	16
Ex 42	0%	8
Ex 44	0%	8
Ex 47	4%	8
Ex 48	3%	8

Ex 49	8%	8
Ex 50	24%	8
Ex 54	6%	8
Ex 55	3%	8

### Antiuterotrophic /Antisulfatase activity

A short model, derived from Purohit's method, was developed for the evaluation *in vivo* of nonestrogenic steroid sulfatase inhibitors.

5 Wistar female rats were ovariectomized and left to rest for 4 weeks. Prior to treatment, the absence of cyclicity was checked by vaginal smears.

Animals were supplemented with estrone sulfate (E<sub>1</sub>S) at 50 µg/kg/day s.c., alone or combined with oral administration of potential sulfatase inhibitors, at 1 mg/kg/day for 4 days. The uteri were removed, freed of adjacent tissue and wet  
10 weighed.

The results are expressed as % of inhibition of the E<sub>1</sub>S induced stimulation.

**Table 3: antiuterotrophic activity**

Compound	% inhibition	Number of animals
6,6,7 COUMATE	86%	48
Ex 42	38%	8
Ex 44	70%	8
Ex 47	62%	8
Ex 48	60%	8
Ex 54	49%	8
Ex 55	81%	16

Ex 55 was chosen as potential inhibitor of steroid sulfatase activity because of lack of estrogenicity and significant inhibition of E<sub>1</sub>S stimulated uterus weight. These *in vivo* results were in good accordance with *in vitro* results obtained in JEG-3 and MCF-7 whole-cell assays.

#### 5 Evaluation of the potency of Ex 55

The activity of Ex 55 on E<sub>1</sub>S stimulated uterus weight was evaluated in relation to the standard inhibitor 6,6,7 COUMATE from 0.03 mg/kg/day to 1 mg/kg/day p.o.

In this study, a last administration was performed 24 hours before the necropsy for E<sub>1</sub>S and E<sub>2</sub> serum levels assays. The uteri were removed, freed of adjacent tissue, wet weighed and immediately deep frozen until the determination of sulfatase activity.

- Inhibition of E<sub>1</sub>S stimulated uterus weight

15

**Table 4**

Dose mg/kg/day	6,6,7 COUMATE	Ex 55
0.03	0%	0%
0.1	13%	0%
0.3	52%	36%
1	84%	72%

- Measure of estrone sulfatase activity in the uterus

Estrone sulfatase activity was measured according to the method described by Purohit et al., with slight modifications. Briefly, uteri were thawed, weighed and homogenized. Aliquots of the supernatant were treated with dextran-coated charcoal and assayed for sulfatase. E<sub>1</sub>S activity was assessed after 30 min of incubation with 5 nM of <sup>3</sup>H-E<sub>1</sub>S and 20 μM of unlabelled E<sub>1</sub>S as substrate. Radioactivity was measured by LSC.

Estrone sulfatase activity was expressed as pmol/h/mg protein and reported as percentage of inhibition *versus* E<sub>1</sub>S.

Table 5

Dose mg/kg/day	6,6,7 COUMATE	Ex 55
0.03	36%	19%
0.1	78%	64%
0.3	96%	96%
1	97%	97%

- Serum estrogen levels

E<sub>1</sub>S and E<sub>2</sub> levels were determined according to the supplier's standard method (DSL, Webster, TX, USA).

5

Table 6: E<sub>1</sub>S levels (ng/ml)

Dose mg/kg/day	6,6,7 COUMATE	Ex 55
0	6.3 ± 0.3	
0.03	24 ± 3.1	17 ± 2.5
0.1	26 ± 2.6	21 ± 2.4
0.3	59 ± 6.4	69 ± 5.9
1	80 ± 5.7	83 ± 2.5



**Table 7: E<sub>2</sub> levels (pg/ml)**

Dose mg/kg/day	6,6,7 COUMATE	Ex 55
0	7.8 ± 0.7	
0.03	33 ± 5.8	31 ± 2.8
0.1	28 ± 2.5	28 ± 1.3
0.3	18 ± 1.1	22 ± 1.2
1	16 ± 1.5	15 ± 0.9

**Hormono-dependent induced xenografts**

5 MCF-7 cells, derived from human breast adenocarcinoma, were injected subcutaneously in ovariectomized athymic nude mice supplemented with estrone sulfate (pellets 0.5 mg/90 day release). Xenograft volumes were determined once weekly. When tumor volumes reached a significant increase, 6,6,7 COUMATE and Ex 55 were orally administered at 0.1mg/kg/day for 6 weeks.

10 Xenografts were measured, removed, weighed, and deep frozen until the determination of steroid sulfatase activity.

**Table 8: Xenograft volume (mm<sup>3</sup>)**

Treatment	Xenograft volume after 6 week treatment
Control placebo	71 ± 8.2
E <sub>1</sub> S pellet (0.5mg/90day release)	1816 ± 337
E <sub>1</sub> S + 6,6,7 COUMATE 0.1mg/kg/day	1854 ± 243
E <sub>1</sub> S + Ex 55 0.1mg/kg/day	1488 ± 233

6,6,7 COUMATE did not inhibit the E<sub>1</sub>S induced stimulation after 6 weeks oral administration at 0.1mg/kg/day. By contrast 18% inhibition were obtained with Ex 55 at the same dose level.

5

**Table 9: Xenograft weight (mg)**

Treatment	Xenograft weight after 6 week treatment
Control placebo	31 ± 3.8
E <sub>1</sub> S pellet (0.5mg/90day release)	1350 ± 277
E <sub>1</sub> S + 6,6,7 COUMATE 0.1mg/kg/day	1467 ± 191
E <sub>1</sub> S + Ex 55 0.1mg/kg/day	877 ± 185

6,6,7 COUMATE did not inhibit xenograft weight while 35% inhibition were obtained with Ex 55.

10


**Table 10: Xenograft steroid sulfatase activity (pmol/h/mg protein)**

Treatment	Sulfatase activity
E <sub>1</sub> S pellet (0.5mg/90day release)	1653 ± 101
E <sub>1</sub> S + 6,6,7 COUMATE 0.1mg/kg/day	540 ± 54
E <sub>1</sub> S + Ex 55 0.1mg/kg/day	263 ± 17

The inhibition of intratumoral steroid sulfatase activity was higher with Ex 55 (84%) than with 6,6,7 COUMATE (67%).

## CLAIMS

1. A compound of formula (I):



5

wherein:

- $R_1$  is hydrogen, a  $(C_1-C_6)$ alkyl, a  $(C_2-C_6)$ alkene, a  $(C_3-C_{12})$ cycloalkyl or a  $(C_3-C_{12})$ cycloalkene wherein the cycloalkyl and the cycloalkene are optionally mono- or disubstituted with a  $(C_1-C_4)$ alkyl;
- 10 -  $R_2$  is hydrogen, a  $(C_1-C_6)$ alkyl or a  $(C_3-C_{12})$ cycloalkyl;
- $R_3$  is hydrogen, a  $(C_1-C_6)$ alkoxy or a halogen;
- $m$  is 0, 1, 2;
- $n$  is 0, 1, 2;
- when  $m$  is 0,  $R_1$  and  $R_2$  can also form together a group  $-(CH_2)_p-$  in which  $p$  is 3, 4
- 15 or 5;
- the dotted line indicates that the sulfamate group is in position 5- or 6- of the benzothiophene ring.

2. The compound according to claim 1, wherein  $R_1$  is hydrogen, a  $(C_1-C_6)$ alkyl, or a  $(C_3-C_{12})$ cycloalkyl which is optionally mono- or disubstituted with a  $(C_1-C_4)$ alkyl.
- 20

3. The compound according to claim 2, wherein  $R_1$  is a  $(C_3-C_{10})$ cycloalkyl which is optionally mono- or disubstituted with a  $(C_1-C_4)$ alkyl.
- 25

4. The compound according to one of claims 1 to 3, wherein m is 0 or 1.
5. The compound according to one of claims 1 to 4, wherein R<sub>2</sub> is hydrogen.
- 5 6. The compound according to one of claims 1 to 5, wherein R<sub>3</sub> is hydrogen.
7. The compound according to one of claims 1 to 6, wherein n is 0 or 2.
8. The compound according to one of claims 1 to 7, wherein the sulfamate  
10 group is in position 6- of the benzothiophene ring.
9. A pharmaceutical composition comprising a compound according to one of claims 1 to 8, and a pharmaceutically acceptable carrier.
- 15 10. A compound according to one of claims 1 to 8 for use as a pharmaceutical.
11. The compound according to claim 10 for use as an inhibitor of steroid sulfatase.
- 20 12. Use of a compound according to one of claims 1 to 8 in the manufacture of a medicament for the treatment or prevention of estrogen-dependent disorders, wherein said compound is optionally combined with one or several sexual endocrine therapeutic agents selected from the group consisting of antiestrogens, SERMs, antiaromatases, antiandrogens, lyase inhibitors, progestins and LH-RH agonists or  
25 antagonists.
13. Use of a compound according to one of claims 1 to 8 in the manufacture of a medicament for the control or management of reproductive functions, wherein said compound is optionally combined with one or several other therapeutic agents  
30 selected from the group consisting of LH-RH agonists or antagonists, estroprogestative contraceptives, progestins, antiprogestins and prostaglandins.

14. Use of a compound according to one of claims 1 to 8 in the manufacture of a medicament for the treatment or prevention of benign or malignant diseases of the breast, the uterus or the ovary, wherein said compound is optionally combined with one or several sexual endocrine therapeutic agents selected from the group consisting of antiestrogens, SERMs, antiaromatases, antiandrogens, lyase inhibitors, progestins  
5 of antiestrogens, SERMs, antiaromatases, antiandrogens, lyase inhibitors, progestins and LH-RH agonists or antagonists.


15. Use of a compound according to one of claims 1 to 8 in the manufacture of a medicament for the treatment or prevention of androgen-dependent diseases, benign  
10 or malignant diseases of the prostate or the testis, wherein said compound is optionally combined with one or several sexual endocrine therapeutic agents selected from the group consisting of antiandrogens, progestins, lyase inhibitors and LH-RH agonists or antagonists.

15 16. Use of a compound according to one of claims 1 to 8 in the manufacture of a medicament for the treatment or prevention of cognitive dysfunction.

17. Use of a compound according to one of claims 1 to 8 in the manufacture of a medicament for the treatment or prevention of immune functions.

FIG. 1

## Formation of estrogens in humans



# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/08811

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D333/54 C07D333/76 A61K31/381 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/008862 A1 (SELCER KYLE W ET AL) 9 January 2003 (2003-01-09) page 2; figure 1 page 4; figure 4	1-17
Y	----- page 4; figure 4	1-17
Y	WOO L W L ET AL: "Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 7, 26 March 1998 (1998-03-26), pages 1068-1083, XP002162181 ISSN: 0022-2623 figures 4,8 -----	1-17

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

21 January 2004

Date of mailing of the international search report

30/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Grassi, D

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/08811

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claim : 1 (part)

Compounds according to claim 1 in which R2 is hydrogen.

2. Claim : 1 (part)

Compounds according to claim 1 in which R2 is (C1-C6)alkyl or (C3-C12)cycloalkyl.

3. Claim : 1 (part)

Compounds according to claim 1 in which R1 and R2 form together a group  $-(CH_2)_p-$ .

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/08811

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2003008862 A1	09-01-2003	US 6433000 B1	13-08-2002
		US 6288107 B1	11-09-2001
		US 6248780 B1	19-06-2001
		AU 748958 B2	13-06-2002
		AU 6408199 A	17-04-2000
		CA 2345988 A1	06-04-2000
		CN 1326345 T	12-12-2001
		EP 1117395 A1	25-07-2001
		JP 2002525322 T	13-08-2002
		WO 0018397 A1	06-04-2000
-----			